Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 133
Filter
1.
Ann Hepatol ; 21: 100191, 2021.
Article in English | MEDLINE | ID: mdl-32331846

ABSTRACT

INTRODUCTION AND OBJECTIVES: N-acetyl-p-aminophenol (APAP)-induced liver injury is a major clinical challenge worldwide. The present study investigated the molecular role of microRNA (miR)-338-3p in the development of APAP-induced acute liver injury. MATERIALS AND METHODS: B6 mice were treated with an miR-338-3p agomir, antagomir, and intraperitoneally injected with APAP 24h later to induce acute liver injury. Histological analysis was performed to evaluate the degree of liver injury. The gene expression of miR-338-3p and its downstream regulators was measured by reverse transcription-quantitative PCR and western blot. The miR target was validated using a luciferase reporter assay. RESULTS: The results revealed that miR-338-3p was significantly upregulated following the intraperitoneal administration of APAP. Augmenting miR-338-3p alleviated acute liver injury caused by APAP overdose, while silencing of miR-338-3p exhibited a detrimental effect. Moreover, miR-338-3p inhibited the expression of pro-inflammatory cytokines by preventing the aberrant activation of inflammatory signaling pathways, including the nuclear factor kappa-B (NF-κB)/mitogen-activated protein kinase (MAPK) signaling pathway. Furthermore, calcium/calmodulin-dependent protein kinase IIα (CAMK IIα) was identified as a direct target of miR-338-3p. CONCLUSION: The present study demonstrated that miR-338-3p inhibited inflammation in APAP-induced acute liver injury.


Subject(s)
Gene Expression Regulation , Hepatitis, Animal/genetics , Hepatitis/genetics , MicroRNAs/genetics , Acetaminophen/toxicity , Acute Disease , Animals , Blotting, Western , Hepatitis, Animal/chemically induced , Hepatitis, Animal/prevention & control , Mice, Inbred C57BL , MicroRNAs/metabolism , Signal Transduction/drug effects
2.
Am J Pathol ; 186(3): 524-38, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26762581

ABSTRACT

The interplay between the inflammatory infiltrate and tissue resident cell populations invokes fibrogenesis. However, the temporal and mechanistic contributions of these cells to fibrosis are obscure. To address this issue, liver inflammation, ductular reaction (DR), and fibrosis were induced in C57BL/6 mice by thioacetamide administration for up to 12 weeks. Thioacetamide treatment induced two phases of liver fibrosis. A rapid pericentral inflammatory infiltrate enriched in F4/80(+) monocytes co-localized with SMA(+) myofibroblasts resulted in early collagen deposition, marking the start of an initial fibrotic phase (1 to 6 weeks). An expansion of bone marrow-derived macrophages preceded a second phase, characterized by accelerated progression of fibrosis (>6 weeks) after DR migration from the portal tracts to the centrilobular site of injury, in association with an increase in DR/macrophage interactions. Although chemokine (C-C motif) ligand 2 (CCL2) mRNA was induced rapidly in response to thioacetamide, CCL2 deficiency only partially abrogated fibrosis. In contrast, colony-stimulating factor 1 receptor blockade diminished C-C chemokine receptor type 2 [CCR2(neg) (Ly6C(lo))] monocytes, attenuated the DR, and significantly reduced fibrosis, illustrating the critical role of colony-stimulating factor 1-dependent monocyte/macrophage differentiation and linking the two phases of injury. In response to liver injury, colony-stimulating factor 1 drives early monocyte-mediated myofibroblast activation and collagen deposition, subsequent macrophage differentiation, and their association with the advancing DR, the formation of fibrotic septa, and the progression of liver fibrosis to cirrhosis.


Subject(s)
Hepatitis, Animal/pathology , Liver Cirrhosis, Experimental/pathology , Macrophage Colony-Stimulating Factor/metabolism , Macrophages/metabolism , Animals , Chemokines/genetics , Chemokines/metabolism , Collagen Type I/metabolism , Disease Models, Animal , Disease Progression , Female , Gene Expression Profiling , Gene Expression Regulation , Hepatitis, Animal/genetics , Hepatitis, Animal/metabolism , Humans , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver Cirrhosis, Experimental/chemically induced , Liver Cirrhosis, Experimental/genetics , Liver Cirrhosis, Experimental/metabolism , Macrophage Colony-Stimulating Factor/genetics , Mice , Mice, Inbred C57BL , Monocytes/metabolism , Oligonucleotide Array Sequence Analysis , Thioacetamide
3.
Development ; 140(3): 639-48, 2013 Feb 01.
Article in English | MEDLINE | ID: mdl-23293295

ABSTRACT

Congenital biliary atresia is an incurable disease of newborn infants, of unknown genetic causes, that results in congenital deformation of the gallbladder and biliary duct system. Here, we show that during mouse organogenesis, insufficient SOX17 expression in the gallbladder and bile duct epithelia results in congenital biliary atresia and subsequent acute 'embryonic hepatitis', leading to perinatal death in ~95% of the Sox17 heterozygote neonates in C57BL/6 (B6) background mice. During gallbladder and bile duct development, Sox17 was expressed at the distal edge of the gallbladder primordium. In the Sox17(+/-) B6 embryos, gallbladder epithelia were hypoplastic, and some were detached from the luminal wall, leading to bile duct stenosis or atresia. The shredding of the gallbladder epithelia is probably caused by cell-autonomous defects in proliferation and maintenance of the Sox17(+/-) gallbladder/bile duct epithelia. Our results suggest that Sox17 plays a dosage-dependent function in the morphogenesis and maturation of gallbladder and bile duct epithelia during the late-organogenic stages, highlighting a novel entry point to the understanding of the etiology and pathogenesis of human congenital biliary atresia.


Subject(s)
Biliary Atresia/genetics , Gene Expression Regulation, Developmental , HMGB Proteins/metabolism , Haploinsufficiency , SOXF Transcription Factors/metabolism , Animals , Animals, Newborn , Bile Ducts/metabolism , Bile Ducts/pathology , Biliary Atresia/pathology , Cell Proliferation , Cholestasis/genetics , Cholestasis/pathology , Embryo, Mammalian/metabolism , Embryo, Mammalian/pathology , Endoplasmic Reticulum Stress , Epithelium/metabolism , Epithelium/pathology , Female , Gallbladder/metabolism , Gallbladder/ultrastructure , HMGB Proteins/genetics , Hepatitis, Animal/genetics , Hepatitis, Animal/metabolism , Hepatitis, Animal/pathology , Hepatocytes/metabolism , Heterozygote , Immunohistochemistry , Liver/metabolism , Liver/ultrastructure , Male , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Pregnancy , SOXF Transcription Factors/genetics , Time Factors
4.
J Biol Chem ; 289(18): 12457-66, 2014 May 02.
Article in English | MEDLINE | ID: mdl-24634219

ABSTRACT

Overexpression of tumor necrosis factor α (TNFα) is a hallmark of many inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and septic shock and hepatitis, making it a potential therapeutic target for clinical interventions. To explore chemical inhibitors against TNFα activity, we applied computer-aided drug design combined with in vitro and cell-based assays and identified a lead chemical compound, (E)-4-(2-(4-chloro-3-nitrophenyl) (named as C87 thereafter), which directly binds to TNFα, potently inhibits TNFα-induced cytotoxicity (IC50 = 8.73 µM) and effectively blocks TNFα-triggered signaling activities. Furthermore, by using a murine acute hepatitis model, we showed that C87 attenuates TNFα-induced inflammation, thereby markedly reducing injuries to the liver and improving animal survival. Thus, our results lead to a novel and highly specific small-molecule TNFα inhibitor, which can be potentially used to treat TNFα-mediated inflammatory diseases.


Subject(s)
Hepatitis, Animal/prevention & control , Inflammation/prevention & control , Small Molecule Libraries/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Blotting, Western , Caspases/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , HL-60 Cells , Hepatitis, Animal/genetics , Hepatitis, Animal/metabolism , Humans , Hydrazones/chemistry , Hydrazones/pharmacology , Inflammation/genetics , Inflammation/metabolism , Jurkat Cells , K562 Cells , MAP Kinase Kinase 4/metabolism , Mice , Mice, Inbred BALB C , Molecular Structure , Protein Binding/drug effects , Receptors, Tumor Necrosis Factor, Type I/metabolism , Signal Transduction/drug effects , Small Molecule Libraries/chemistry , Structure-Activity Relationship , Surface Plasmon Resonance , Thiazoles/chemistry , Thiazoles/pharmacology , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factor-alpha/pharmacology
6.
Eur J Immunol ; 44(4): 1119-29, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24448964

ABSTRACT

Extracellular adenosine regulates inflammatory responses via the A2A adenosine receptor (A2AR). A2AR deficiency results in much exaggerated acute hepatitis, indicating nonredundancy of adenosine-A2AR pathway in inhibiting immune activation. To identify a critical target of immunoregulatory effect of extracellular adenosine, we focused on NKT cells, which play an indispensable role in hepatitis. An A2AR agonist abolished NKT-cell-dependent induction of acute hepatitis by concanavalin A (Con A) or α-galactosylceramide in mice, corresponding to downregulation of activation markers and cytokines in NKT cells and of NK-cell co-activation. These results show that A2AR signaling can downregulate NKT-cell activation and suppress NKT-cell-triggered inflammatory responses. Next, we hypothesized that NKT cells might be under physiological control of the adenosine-A2AR pathway. Indeed, both Con A and α-galactosylceramide induced more severe hepatitis in A2AR-deficient mice than in WT controls. Transfer of A2AR-deficient NKT cells into A2AR-expressing recipients resulted in exaggeration of Con A-induced liver damage, suggesting that NKT-cell activation is controlled by endogenous adenosine via A2AR, and this physiological regulatory mechanism of NKT cells is critical in the control of tissue-damaging inflammation. The current study suggests the possibility to manipulate NKT-cell activity in inflammatory disorders through intervention to the adenosine-A2AR pathway.


Subject(s)
Adenosine/immunology , Hepatitis, Animal/immunology , Natural Killer T-Cells/immunology , Receptor, Adenosine A2A/immunology , Adenosine/analogs & derivatives , Adenosine/pharmacology , Adenosine A2 Receptor Agonists/immunology , Adenosine A2 Receptor Agonists/pharmacology , Adenosine A2 Receptor Antagonists/immunology , Adenosine A2 Receptor Antagonists/pharmacology , Animals , Cells, Cultured , Concanavalin A , Flow Cytometry , Galactosylceramides , Hepatitis, Animal/chemically induced , Hepatitis, Animal/genetics , Interferon-gamma/immunology , Interferon-gamma/metabolism , Liver/immunology , Liver/metabolism , Liver/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Natural Killer T-Cells/drug effects , Natural Killer T-Cells/metabolism , Phenethylamines/immunology , Phenethylamines/pharmacology , Receptor, Adenosine A2A/metabolism , Triazines/immunology , Triazines/pharmacology , Triazoles/immunology , Triazoles/pharmacology , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism
7.
PLoS Pathog ; 9(6): e1003438, 2013.
Article in English | MEDLINE | ID: mdl-23818848

ABSTRACT

Hepatitis C virus (HCV) is among the most relevant causes of liver cirrhosis and hepatocellular carcinoma. Research is complicated by a lack of accessible small animal models. The systematic investigation of viruses of small mammals could guide efforts to establish such models, while providing insight into viral evolutionary biology. We have assembled the so-far largest collection of small-mammal samples from around the world, qualified to be screened for bloodborne viruses, including sera and organs from 4,770 rodents (41 species); and sera from 2,939 bats (51 species). Three highly divergent rodent hepacivirus clades were detected in 27 (1.8%) of 1,465 European bank voles (Myodes glareolus) and 10 (1.9%) of 518 South African four-striped mice (Rhabdomys pumilio). Bats showed anti-HCV immunoblot reactivities but no virus detection, although the genetic relatedness suggested by the serologic results should have enabled RNA detection using the broadly reactive PCR assays developed for this study. 210 horses and 858 cats and dogs were tested, yielding further horse-associated hepaciviruses but none in dogs or cats. The rodent viruses were equidistant to HCV, exceeding by far the diversity of HCV and the canine/equine hepaciviruses taken together. Five full genomes were sequenced, representing all viral lineages. Salient genome features and distance criteria supported classification of all viruses as hepaciviruses. Quantitative RT-PCR, RNA in-situ hybridisation, and histopathology suggested hepatic tropism with liver inflammation resembling hepatitis C. Recombinant serology for two distinct hepacivirus lineages in 97 bank voles identified seroprevalence rates of 8.3 and 12.4%, respectively. Antibodies in bank vole sera neither cross-reacted with HCV, nor the heterologous bank vole hepacivirus. Co-occurrence of RNA and antibodies was found in 3 of 57 PCR-positive bank vole sera (5.3%). Our data enable new hypotheses regarding HCV evolution and encourage efforts to develop rodent surrogate models for HCV.


Subject(s)
Evolution, Molecular , Genome, Viral , Hepacivirus , Hepatitis C Antibodies/blood , Hepatitis C , Hepatitis, Animal , RNA, Viral , Rodentia , Animals , Base Sequence , Cats , Dogs , Hepacivirus/genetics , Hepacivirus/metabolism , Hepatitis C/blood , Hepatitis C/genetics , Hepatitis C/virology , Hepatitis, Animal/blood , Hepatitis, Animal/genetics , Hepatitis, Animal/virology , Horses , Molecular Sequence Data , RNA, Viral/blood , RNA, Viral/genetics , Rodentia/blood , Rodentia/virology
8.
J Dairy Sci ; 98(12): 8856-68, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26409958

ABSTRACT

During the periparturient phase, cows are typically in an inflammation-like condition, and it has been suggested that inflammation associated with the development of stress of the endoplasmic reticulum (ER) in the liver contributes to the development of fatty liver syndrome and ketosis. In the present study, we investigated the hypothesis that feeding grape seed and grape marc meal extract (GSGME) as a plant extract rich in flavonoids attenuates inflammation and ER stress in the liver of dairy cows. Two groups of cows received either a total mixed ration as a control diet or the same total mixed ration supplemented with 1% of GSGME over the period from wk 3 prepartum to wk 9 postpartum. Dry matter intake during wk 3 to 9 postpartum was not different between the 2 groups. However, the cows fed the diet supplemented with GSGME had an increased milk yield and an increased daily milk protein yield. Cows supplemented with GSGME moreover had a significantly reduced mRNA abundancy of fibroblast growth factor (FGF) 21, a stress hormone induced by various stress conditions, in the liver in wk 1 and 3 postpartum. In contrast, mRNA abundances of a total of 3 genes involved in inflammation and 14 genes involved in ER stress response, as well as concentrations of triacylglycerols and cholesterol, in liver samples of wk 1 and 3 postpartum did not differ between the 2 groups. Overall, this study shows that supplementation of GSGME did not influence inflammation or ER stress in the liver but increased milk yield, an effect that could be due to effects on ruminal metabolism.


Subject(s)
Cattle Diseases/prevention & control , Endoplasmic Reticulum Stress/drug effects , Grape Seed Extract/administration & dosage , Hepatitis, Animal/prevention & control , Lactation/drug effects , Vitis/chemistry , Animals , Cattle , Cattle Diseases/physiopathology , Diet/veterinary , Dietary Supplements , Endoplasmic Reticulum Stress/genetics , Female , Flavonoids/administration & dosage , Gene Expression/drug effects , Hepatitis, Animal/genetics , Hepatitis, Animal/physiopathology , Lactation/physiology , Lipids/analysis , Liver/chemistry , Milk , Parturition/physiology , Seeds
9.
J Lipid Res ; 55(3): 421-30, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24347528

ABSTRACT

Obesity-induced liver inflammation can drive insulin resistance. HDL has anti-inflammatory properties, so we hypothesized that low levels of HDL would perpetuate inflammatory responses in the liver and that HDL treatment would suppress liver inflammation and insulin resistance. The aim of this study was to investigate the effects of lipid-free apoAI on hepatic inflammation and insulin resistance in mice. We also investigated apoAI as a component of reconstituted HDLs (rHDLs) in hepatocytes to confirm results we observed in vivo. To test our hypothesis, C57BL/6 mice were fed a high-fat diet (HFD) for 16 weeks and administered either saline or lipid-free apoAI. Injections of lipid-free apoAI twice a week for 2 or 4 weeks with lipid-free apoAI resulted in: i) improved insulin sensitivity associated with decreased systemic and hepatic inflammation; ii) suppression of hepatic mRNA expression for key transcriptional regulators of lipogenic gene expression; and iii) suppression of nuclear factor κB (NF-κB) activation. Human hepatoma HuH-7 cells exposed to rHDLs showed suppressed TNFα-induced NF-κB activation, correlating with decreased NF-κB target gene expression. We conclude that apoAI suppresses liver inflammation in HFD mice and improves insulin resistance via a mechanism that involves a downregulation of NF-κB activation.


Subject(s)
Hepatitis, Animal/prevention & control , Insulin Resistance , Lipoproteins, HDL/pharmacology , Liver/drug effects , Animals , Apolipoprotein A-I/metabolism , Apolipoprotein A-I/pharmacology , Blood Glucose/metabolism , Cell Line, Tumor , Diet, High-Fat , Gene Expression/drug effects , Glucose/metabolism , Glucose Tolerance Test , Hepatitis, Animal/genetics , Hepatitis, Animal/metabolism , Humans , Insulin/blood , Interferon-gamma/blood , Interferon-gamma/genetics , Interleukin-6/blood , Interleukin-6/genetics , Lipoproteins, HDL/metabolism , Liver/metabolism , Liver/pathology , Male , Mice , Mice, Inbred C57BL , NF-kappa B/metabolism , Phosphoenolpyruvate Carboxykinase (ATP)/genetics , Reverse Transcriptase Polymerase Chain Reaction , Triglycerides/blood , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/genetics
10.
Mol Cell Biochem ; 388(1-2): 185-93, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24337968

ABSTRACT

The Long-Evans Cinnamon (LEC) rat is an animal model for Wilson's disease. This animal is genetically predisposed to copper accumulation in the liver, increased oxidative stress, accumulation of DNA damage, and the spontaneous development of hepatocellular carcinoma. Thus, this animal model is useful for studying the relationship of endogenous DNA damage to spontaneous carcinogenesis. In this study, we have investigated the apurinic/apyrimidinic endonuclease 1 (APE1)-mediated excision repair of endogenous DNA damage, apurinic/apyrimidinic (AP)-sites, which is highly mutagenic and implicated in human cancer. We found that the activity was reduced in the liver extracts from the acute hepatitis period of LEC rats as compared with extracts from the age-matched Long-Evans Agouti rats. The acute hepatitis period had also a heightened oxidative stress condition as assessed by an increase in oxidized glutathione level and loss of enzyme activity of glyceraldehyde 3-phosphate dehydrogenase, a key redox-sensitive protein in cells. Interestingly, the activity reduction was not due to changes in protein expression but apparently by reversible protein oxidation as the addition of reducing agents to extracts of the liver from acute hepatitis period reactivated APE1 activity and thus, confirmed the oxidation-mediated loss of APE1 activity under increased oxidative stress. These findings show for the first time in an animal model that the repair mechanism of AP-sites is impaired by increased oxidative stress in acute hepatitis via redox regulation which contributed to the increased accumulation of mutagenic AP-sites in liver DNA.


Subject(s)
Carcinoma, Hepatocellular/genetics , DNA Repair/genetics , DNA-(Apurinic or Apyrimidinic Site) Lyase/metabolism , Hepatitis, Animal/genetics , Liver Neoplasms/genetics , Adenosine Triphosphatases/genetics , Animals , Cation Transport Proteins/genetics , Cell Transformation, Neoplastic , Copper , Copper-Transporting ATPases , DNA Damage/genetics , DNA-(Apurinic or Apyrimidinic Site) Lyase/genetics , Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)/metabolism , Inflammation , Liver/pathology , Oxidation-Reduction , Oxidative Stress , Rats , Rats, Inbred LEC , Reactive Oxygen Species/metabolism
11.
J Clin Immunol ; 33(3): 630-9, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23184091

ABSTRACT

In this study we explored the effects of microRNA let-7a on Con A-induced hepatitis and its possible mechanisms involved. We demonstrated that IL-6 and IL-17 expression were significantly upregulated in the liver following Con A treatment and IL-6 level was correlated with the IL-17 expression. To explore whether let-7a may have therapeutic effect on Con A-induced hepatitis, mice was infected with a lentiviral vector containing the let-7a sequence 7 days before Con A treatment. Significantly reduced Th17 cells and remarkably increased regulatory T cells frequency in the liver tissue were found as compared to control mice. It was accompanied by a significant decreased level of inflammatory cytokines as TNF-α, IL-6 and IFN-γ in the serum, and an decreased level of Th17 lineage-specific genes such as Il17a, Il17f, Il21 and Il23r. let-7a was further found to inhibit Th17 differentiation by downregulating IL-6 secretion. It may represent as a novel therapeutic strategy in treating immune-mediated inflammatory hepatitis.


Subject(s)
Cell Differentiation , Hepatitis, Animal/genetics , Hepatitis, Animal/immunology , Interleukin-6/immunology , MicroRNAs/genetics , Th17 Cells/cytology , Animals , Cell Differentiation/genetics , Cell Differentiation/immunology , Cell Lineage/genetics , Concanavalin A/adverse effects , Hepatitis, Animal/chemically induced , Humans , Interleukin-17/metabolism , Interleukin-6/metabolism , Liver/immunology , Liver/metabolism , Liver/pathology , Mice , Th17 Cells/immunology , Th17 Cells/metabolism
12.
Eur J Immunol ; 41(8): 2341-8, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21557213

ABSTRACT

Interleukin-33 (IL-33) is thought to be released during cellular death as an alarming cytokine during the acute phase of disease, but its regulation in vivo is poorly understood. We investigated the expression of IL-33 in two mouse models of acute hepatitis by administering either carbon tetrachloride (CCl(4) ) or concanavalin A (ConA). IL-33 was overexpressed in both models but with a stronger induction in ConA-induced hepatitis. IL-33 was weakly expressed in vascular and sinusoidal endothelial cells from normal liver and was clearly induced in CCl(4) -treated mice. Surprisingly, we found that hepatocytes strongly expressed IL-33 exclusively in the ConA model. CD1d knock-out mice, which are deficient in NKT cells and resistant to ConA-induced hepatitis, no longer expressed IL-33 in hepatocytes following ConA administration. Interestingly, invariant NKT (iNKT) cells adoptively transferred into ConA-treated CD1d KO mouse restored IL-33 expression in hepatocytes. This strongly suggests that NKT cells are responsible for the induction of IL-33 in hepatocytes.


Subject(s)
Hepatitis, Animal/genetics , Hepatocytes/metabolism , Interleukins/genetics , Natural Killer T-Cells/metabolism , Acute Disease , Adoptive Transfer , Animals , Antigens, CD1d/genetics , Antigens, CD1d/metabolism , Carbon Tetrachloride , Concanavalin A , Female , Flow Cytometry , Fluorescent Antibody Technique , Gene Expression , Hepatitis, Animal/chemically induced , Hepatitis, Animal/metabolism , Hepatocytes/drug effects , Hepatocytes/pathology , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Interleukin-33 , Interleukin-6/genetics , Interleukin-6/metabolism , Interleukins/metabolism , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , Reverse Transcriptase Polymerase Chain Reaction , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
13.
Pharmacol Res ; 65(5): 523-30, 2012 May.
Article in English | MEDLINE | ID: mdl-22402395

ABSTRACT

The anti-inflammatory properties of the flavonol quercetin have been intensively investigated using in vitro cell systems and are to a great extent reflected by changes in the expression of inflammatory markers. However, information relating to the degree at which quercetin affects inflammatory gene expression in vivo is limited. Recently, micro RNAs (miRNAs) have been identified as powerful post-transcriptional gene regulators. The effect of quercetin on miRNA regulation in vivo is largely unknown. Laboratory mice were fed for six weeks with control or quercetin enriched high fat diets and biomarkers of inflammation as well as hepatic levels of miRNAs previously involved in inflammation (miR-125b) and lipid metabolism (miR-122) were determined. We found lower mRNA steady state levels of the inflammatory genes interleukin 6, C-reactive protein, monocyte chemoattractant protein 1, and acyloxyacyl hydrolase in quercetin fed mice. In addition we found evidence for an involvement of redox factor 1, a modulator of nuclear factor κB signalling, on the attenuation of inflammatory gene expression mediated by dietary quercetin. Furthermore, the results demonstrate that hepatic miR-122 and miR-125b concentrations were increased by dietary quercetin supplementation and may therefore contribute to the gene-regulatory activity of quercetin in vivo.


Subject(s)
DNA-(Apurinic or Apyrimidinic Site) Lyase/metabolism , Inflammation/drug therapy , Inflammation/genetics , Liver/drug effects , Liver/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Quercetin/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , C-Reactive Protein/genetics , Carboxylic Ester Hydrolases/genetics , Chemokine CCL2/genetics , Dietary Supplements , Female , Gene Expression Regulation/drug effects , Hepatitis, Animal/drug therapy , Hepatitis, Animal/genetics , Hepatitis, Animal/metabolism , Inflammation Mediators/metabolism , Interleukin-6/genetics , Lipid Metabolism/drug effects , Lipids/blood , Mice , Mice, Inbred C57BL , Oxidative Stress/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism
14.
Tissue Antigens ; 77(1): 30-5, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20946186

ABSTRACT

Doberman hepatitis (DH) is a chronic and progressive inflammatory liver disease that mainly affects female dogs. The high incidence of chronic hepatitis in Dobermans is suggestive of a genetic predisposition. DH is characterized by mononuclear cell infiltration and copper accumulation in the liver and major histocompatibility complex (MHC) class II antigen expression in the hepatocytes. In dogs, the MHC is referred to as the dog leukocyte antigen (DLA) system. In this study, the potential role of DLA genes in DH was investigated by sequence-based typing in the exon 2 of DLA-DRB1, -DQA1 and -DQB1. The case group comprised 37 Dobermans with subclinical or clinical DH. The control group consisted of 37 healthy Dobermans, with normal liver enzyme values and without immunosuppressive medication. The control dogs were over 10 years old to include dogs with the lowest genetic risk of DH. Our results indicate that Dobermans with homozygous DLA-DRB1*00601/DQA1*00401/DQB1*01303 [odds ratio (OR) = 14.9, confidence limit (CL) = 3.1-71.7, P < 0.00005], especially with homozygosity for DLA-DRB1*00601 (P < 0.0005), are susceptible to DH. The DQ heterodimer DLA-DQA1*00901/DQB1*00101 and the allele DLA-DRB1*01501 appear to confer protection against DH (P < 0.001). Allele and haplotype frequencies were compared using chi-squared statistics. The disease shows a complex pattern of inheritance, but the observed DLA class II association with DH suggests a role for the immune system in the development of the disease.


Subject(s)
Dog Diseases/genetics , Dog Diseases/immunology , Genetic Predisposition to Disease , Hepatitis, Animal/genetics , Hepatitis, Animal/immunology , Histocompatibility Antigens Class II/genetics , Histocompatibility Antigens Class II/immunology , Animals , Case-Control Studies , Dogs , Hepatitis, Animal/physiopathology , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology
15.
Tissue Antigens ; 78(6): 446-50, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22077625

ABSTRACT

Doberman hepatitis (DH) is associated with homozygous DLA-DRB1*00601/DQA1*00401/DQB1*01303 indicating a role for the immune system in the development of the disease. The dog leucocyte antigen (DLA) class II expression is controlled at the transcriptional level with proximal promoters. Differential expression of DLA class II molecules of antigen-presenting cells is reported to affect susceptibility to or protection from different immune-mediated diseases. The aim of this study was to evaluate, whether the variation in promoter areas of homozygous DLA-DRB1*00601/DQA1*00401/DQB1*01303 Dobermans could explain why some dogs become afflicted with DH and others do not. Our findings suggest that promoter variants are not associated as risk modifiers in homozygous DLA-DRB1*00601/DQA1*00401/DQB1*01303 Dobermans, but additional factors are needed. Nevertheless, our study indicates that the whole DLA block is associated to the disease.


Subject(s)
Gene Expression Regulation , Hepatitis, Animal/genetics , Histocompatibility Antigens Class II/genetics , Promoter Regions, Genetic/genetics , Animals , Dogs , Hepatitis, Animal/immunology , Histocompatibility Antigens Class II/immunology , Promoter Regions, Genetic/immunology
16.
Vet Pathol ; 48(4): 839-45, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21118800

ABSTRACT

Molecular regulation of fibrosis in chronic canine hepatitis is poorly understood. The authors employed quantitative polymerase chain reaction (PCR) to determine the expression levels of genes reported to be related to fibrosis in other species (human, mouse, and rat) and to elucidate the relationship of these genes with the degree of fibrosis and the presence or absence of ascites and/or jaundice in dogs with hepatitis. Nine fibrosis-related genes were assayed: PDGFB, PDGFD, MMP2, TIMP1, THBS1, COL1A1, COL3A1, TGFB1, and TGFB2. Liver samples of 15 dogs with chronic hepatitis and 4 healthy control dogs were obtained via laparoscopic biopsy and subjected to histologic and quantitative PCR analyses. The expression of all 9 genes showed significant positive correlation (P<.01, r>.70) with the degree of fibrosis. Furthermore, the expression levels of all genes except TGFB1 were significantly higher (P<.05) in dogs with hepatic failure-related symptoms (ascites/jaundice). Results suggest that these 9 genes are integral to the development of fibrosis in canine chronic hepatitis.


Subject(s)
Dog Diseases/genetics , Gene Expression Regulation/physiology , Hepatitis, Animal/genetics , Liver Cirrhosis/veterinary , Animals , Chronic Disease , Dog Diseases/pathology , Dogs , Female , Hepatitis, Animal/pathology , Liver/pathology , Liver Cirrhosis/genetics , Liver Cirrhosis/pathology , Male
17.
Vet Pathol ; 48(3): 627-41, 2011 May.
Article in English | MEDLINE | ID: mdl-21097715

ABSTRACT

Feline lymphocytic cholangitis is a poorly characterized disease complex with respect to histologic lesions, immunophenotype, and etiopathogenesis. Seventy-eight cases of feline lymphocytic cholangitis (n = 51) and feline hepatic lymphoma (n = 27) were reviewed using standardized histopathology, immunophenotyping (B cell and T cell), polymerase chain reaction for T-cell receptor (TCR) gene rearrangement, and fluorescence in situ hybridization (FISH) for eubacteria. Five histopathologic features in cases of lymphocytic cholangitis assisted in its differentiation from hepatic lymphoma: bile duct targeting (n = 32, 62.7%), ductopenia (n = 9, 17.6%), peribiliary fibrosis (n = 37, 72.5%), portal B-cell aggregates (n = 36, 70.6%), and portal lipogranulomas (n = 38, 74.5%). The majority of lymphocytic cholangitis cases (n = 35, 68.6%) were T cell predominant; 15 (29.4%) had an equal mix of B cells and T cells, and 1 (1.9%) had a B cell-predominant infiltrate; 66.6% of hepatic lymphoma cases were T-cell lymphomas. TCR clonality results were unexpected, with 17.1% of cases of lymphocytic cholangitis having clonal or oligoclonal populations and with T-cell lymphomas having variable TCR clonality (63.6% clonal or oligoclonal, 36.3% polyclonal). The majority of lymphocytic cholangitis (n = 32 of 36, 88.8%) and all hepatic lymphoma cases had no detectable eubacteria using FISH. As demonstrated here, bile duct targeting, ductopenia, peribiliary fibrosis, portal B-cell aggregates, and portal lipogranulomas are lymphocytic cholangitis features that, along with polyclonal TCR (83%), help differentiate it from hepatic lymphoma. No strong evidence was found implicating in situ bacterial colonization as an etiopathogenesis of lymphocytic cholangitis.


Subject(s)
Cat Diseases/pathology , Cholangitis/veterinary , Hepatitis, Animal/pathology , Immunophenotyping/veterinary , Animals , Cat Diseases/genetics , Cat Diseases/microbiology , Cats , Cholangitis/genetics , Cholangitis/pathology , Female , Genetic Predisposition to Disease , Hepatitis, Animal/genetics , Immunohistochemistry/veterinary , Liver/pathology , Male , Polymerase Chain Reaction , Retrospective Studies
18.
BMC Genomics ; 11: 240, 2010 Apr 15.
Article in English | MEDLINE | ID: mdl-20398290

ABSTRACT

BACKGROUND: Due to the high morbidity and mortality of fulminant hepatitis, early diagnosis followed by early effective treatment is the key for prognosis improvement. So far, little is known about the gene expression changes in the early stage of this serious illness. Identification of the genes related to the very early stage of fulminant hepatitis development may provide precise clues for early diagnosis. RESULTS: Balb/C mice were used for ConA injection to induce fulminant hepatitis that was confirmed by pathological and biochemical examination. After a gene chip-based screening, the data of gene expression in the liver, was further dissected by ANOVA analysis, gene expression profiles, gene network construction and real-time RT-PCR. At the very early stage of ConA-triggered fulminant hepatitis, totally 1,473 genes with different expression variations were identified. Among these, 26 genes were finally selected for further investigation. The data from gene network analysis demonstrate that two genes, MPDZ and Acsl1, localized in the core of the network. CONCLUSIONS: At the early stages of fulminant hepatitis, expression of twenty-six genes involved in protein transport, transcription regulation and cell metabolism altered significantly. These genes form a network and have shown strong correlation with fulminant hepatitis development. Our study provides several potential targets for the early diagnosis of fulminant hepatitis.


Subject(s)
Gene Expression Profiling , Hepatitis, Animal/genetics , Liver Failure, Acute/genetics , Algorithms , Analysis of Variance , Animals , Concanavalin A , Hepatitis, Animal/chemically induced , Liver Failure, Acute/chemically induced , Mice , Mice, Inbred BALB C , Oligonucleotide Array Sequence Analysis
19.
J Exp Med ; 131(4): 843-50, 1970 Apr 01.
Article in English | MEDLINE | ID: mdl-4317219

ABSTRACT

Peritoneal macrophages from genetically resistant C(3)H mice and genetically susceptible Princeton (PRI) mice adsorbed the MHV (PRI) strain of mouse hepatitis virus equally well. The difference between the permissive cells and the nonpermissive ones seems to reside in the ability of the former to "eclipse" the virus and, subsequently, support virus replication. C(3)H cells exposed to low multiplicities of the virus remained intact with no demonstrable viral replication. Virus, taken up by the resistant cells, was protected from heat and underwent slow inactivation while few or no virus particles were released into the medium.


Subject(s)
Macrophages/immunology , Murine hepatitis virus/immunology , Adsorption , Animals , Culture Techniques , Genes , Hepatitis, Animal/genetics , Horses , Hot Temperature , Immunoassay , Mice , Murine hepatitis virus/analysis , Murine hepatitis virus/growth & development , Murine hepatitis virus/isolation & purification , Neutralization Tests , Species Specificity , Virus Replication
20.
J Exp Med ; 131(4): 851-62, 1970 Apr 01.
Article in English | MEDLINE | ID: mdl-4317220

ABSTRACT

A variant mouse hepatitis virus MHV(C(3)H) to which cultured peritoneal macrophages from both PRI and C(3)H mice were susceptible was isolated from stocks of the MHV(PRI) strain of mouse hepatitis virus. It was cloned on C(3)H macrophage monolayers and killed both adult PRI and C(3)H mice when injected intraperitoneally. This new variant was antigenically indistinguishable from the wild type virus. While the emergence of the variant virus was delayed in the course of infecting C(3)H macrophages with large inocula of MHV(PRI), the second passage grew to a high titer in both cell types without delay. Thus, adaptation to the new host was immediate. Interference, apparently not interferon-mediated, between the two variant viruses may have been the cause for the delay in the emergence of the variant virus. The delayed destruction of C(3)H-cultured macrophages by large inocula of MHV(PRI) uniformly resulted in the emergence of MHV(C(3)H). Whether the new variant emerged as a result of a selection of a pre-existing stable mutant or was conditioned by "growth" in the resistant host was not determined.


Subject(s)
Macrophages/immunology , Murine hepatitis virus/classification , Animals , Culture Techniques , Hepatitis, Animal/genetics , Immunoassay , Interferons/analysis , Mice , Murine hepatitis virus/growth & development , Murine hepatitis virus/immunology , Murine hepatitis virus/isolation & purification , Murine hepatitis virus/pathogenicity , Neutralization Tests , Species Specificity , Virulence
SELECTION OF CITATIONS
SEARCH DETAIL